161 related articles for article (PubMed ID: 37407963)
41. Increase EGFR Mutations Detection Rate in Lung Adenocarcinoma by Real-Time PCR Screening Followed by Direct Sequencing.
Er TK; Lin CW; Liu TC; Chen CC; Wang LH; Hsieh LL; Tsai WC
Appl Immunohistochem Mol Morphol; 2015; 23(5):343-8. PubMed ID: 25961746
[TBL] [Abstract][Full Text] [Related]
42. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Zhang Y; Wang Q; Han ZG; Shan L
Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
[TBL] [Abstract][Full Text] [Related]
43. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
[TBL] [Abstract][Full Text] [Related]
44. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.
Shaozhang Z; Ming Z; Haiyan P; Aiping Z; Qitao Y; Xiangqun S
Med Oncol; 2014 May; 31(5):926. PubMed ID: 24748405
[TBL] [Abstract][Full Text] [Related]
45. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?
Vigliar E; Malapelle U; Bellevicine C; de Luca C; Troncone G
Cytopathology; 2015 Oct; 26(5):312-7. PubMed ID: 25376259
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
[TBL] [Abstract][Full Text] [Related]
47. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
48. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
Girard N; Sima CS; Jackman DM; Sequist LV; Chen H; Yang JC; Ji H; Waltman B; Rosell R; Taron M; Zakowski MF; Ladanyi M; Riely G; Pao W
Eur Respir J; 2012 Feb; 39(2):366-72. PubMed ID: 21778168
[TBL] [Abstract][Full Text] [Related]
49. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study.
Cheng Y; Wang Y; Zhao J; Liu Y; Gao H; Ma K; Zhang S; Xin H; Liu J; Han C; Zhu Z; Wang Y; Chen J; Wen F; Li J; Zhang J; Zheng Z; Dai Z; Piao H; Li X; Li Y; Zhong M; Ma R; Zhuang Y; Xu Y; Qu Z; Yang H; Pan C; Yang F; Zhang D; Li B
Thorac Cancer; 2018 Nov; 9(11):1461-1469. PubMed ID: 30253083
[TBL] [Abstract][Full Text] [Related]
50. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
51. Predicting EGFR mutational status from pathology images using a real-world dataset.
Pao JJ; Biggs M; Duncan D; Lin DI; Davis R; Huang RSP; Ferguson D; Janovitz T; Hiemenz MC; Eddy NR; Lehnert E; Cabili MN; Frampton GM; Hegde PS; Albacker LA
Sci Rep; 2023 Mar; 13(1):4404. PubMed ID: 36927889
[TBL] [Abstract][Full Text] [Related]
52. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
53. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
54. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
[TBL] [Abstract][Full Text] [Related]
55. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
56. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.
Ellison G; Zhu G; Moulis A; Dearden S; Speake G; McCormack R
J Clin Pathol; 2013 Feb; 66(2):79-89. PubMed ID: 23172555
[TBL] [Abstract][Full Text] [Related]
57. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
Chatterjee K; Ray A; Chattopadhyay B
Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
[TBL] [Abstract][Full Text] [Related]
58. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
[TBL] [Abstract][Full Text] [Related]
59. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.
Salto-Tellez M; Tsao MS; Shih JY; Thongprasert S; Lu S; Chang GC; Au JS; Chou TY; Lee JS; Shi YK; Radzi A; Kang JH; Kim SW; Tan SY; Yang JC
J Thorac Oncol; 2011 Oct; 6(10):1663-9. PubMed ID: 21869714
[TBL] [Abstract][Full Text] [Related]
60. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
